About 15,000 to 25,000 subjects will be screened. Their information will be collected,venous blood will be sampled, their serum antibody levels will be detected, and theincidence of COVID-19 wil be followed up.
Data of the following will be collected:
1. Demographic data,including Name, Gender, Ethnic groups, ID Card number (age
automatically calculated), Height/weight (automatic BMI calculation);
2. Previous disease/surgical history; 3. Previous COVID-19 infections; 4. COVID-19
vaccination history; 5. Infection after this screening; 6. Screening information for
COVID-19 antibodies.
Atibody level against SARS-CoV-2 will be test.
Inclusion Criteria:
- The age when signing ICF should be ≥3 year, male or female.
- The Subject and/or guardian or client of both parties are able to sign a written ICF
and voluntarily participate in the trial, fully understand the trial procedure, the
risks of participating in the study.
- Healthy subjects or subjects with stable underlying diseases. Stable underlying
diseases were defined as those who were in stable condition at least 3 months before
inclusion in the study, had no significant change in treatment regimen and had not
been admitted to hospital due to disease progression.
Exclusion Criteria:
- a history of contraindications for venous blood collection such as thrombocytopenia
or other clotting disorders.
- Current severe or uncontrollable cardiovascular disease, endocrine disease, blood
and lymphatic system disease, liver and kidney disease, respiratory system disease,
metabolic and skeletal system disease, or malignancy.
- If it is not in line with the benefit maximization of the subjects, the investigator
determines that it is not suitable to participate in clinical research.
Dazhu County Center for Disease Control and Prevention
Dazhou, Sichuan, China
Investigator: Bo Zhou, Bachelor's
Xinjie Yang, M.D.
86-010-58628288
xinjie_yang@sinocelltech.com
Bo Zhou, M.D., Principal Investigator
Dazhu County Center for Disease Control and Prevention